

1 **Differences in disease burdens across human populations are**
2 **governed more by neutral evolution than by natural selection**

3

4 Ujani Hazra¹ and Joseph Lachance^{1*}

5

6 ¹ School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA

7

8 *Corresponding author: Joseph Lachance (joseph.lachance@biology.gatech.edu)

9

10

11 **Keywords:** evolutionary genetics, human genomics, natural selection, neutral evolution,
12 polygenic risk scores

13 **Abstract**

14 The prevalence of most complex diseases varies across human populations, and a
15 combination of socioeconomic and biological factors drives these differences. Likewise,
16 divergent evolutionary histories can lead to different genetic architectures of disease,
17 where allele frequencies and linkage disequilibrium patterns at disease-associated loci
18 differ across global populations. However, it is presently unknown how much natural
19 selection contributes to the health inequities of complex polygenic diseases. Here, we
20 focus on ten hereditary diseases with the largest global disease burden in terms of
21 mortality rates (e.g., coronary artery disease, stroke, type 2 diabetes, and lung cancer).
22 Leveraging multiple GWAS and polygenic risk scores for each disease, we examine
23 signatures of selection acting on sets of disease-associated variants. First, on a species
24 level, we find that genomic regions associated with complex diseases are enriched for
25 signatures of background selection. Second, tests of polygenic adaptation incorporating
26 demographic histories of continental super-populations indicate that most complex
27 diseases are primarily governed by neutral evolution. Third, we focus on a finer scale,
28 testing for recent positive selection on a population level. We find that even though some
29 disease-associated loci have undergone recent selection (extreme values of integrated
30 haplotype scores), sets of disease-associated loci are not enriched for selection when
31 compared to baseline distributions of control SNPs. Collectively, we find that recent
32 natural selection has had a negligible role in driving differences in the genetic risk of
33 complex diseases between human populations. These patterns are consistent with the
34 late age of onset of many complex diseases.

35 **Introduction**

36 Disease risks have evolved substantially over recent human history (Crespi 2010;
37 Quintana-Murci 2016). Increases in population size and changes in eating habits following
38 the agricultural revolution have led to an increase in nutritional and infectious diseases
39 and a decline in the overall health of many populations (Mummert, et al. 2011). While
40 mortality from infectious diseases has decreased significantly in the 20th century
41 (Armstrong, et al. 1999), the “transition to modernity” now puts the global population at a
42 greater risk of non-communicable diseases (Corbett, et al. 2018). Indeed, the leading
43 causes of death in sub-Saharan Africa have shifted from communicable diseases in
44 children to non-communicable diseases in adults over the past three decades, with
45 stroke, depression, diabetes, and ischemic heart disease dominating among middle-
46 income countries (Bigna and Noubiap 2019).

47 Substantial heterogeneity in the mortality rates of non-communicable diseases
48 exists across the globe (Warnecke, et al. 2008; Allen, et al. 2017). For example, disease
49 burdens of stroke are high in Asia (Kim and Johnston 2011), and men of African descent
50 suffer the highest mortality from prostate cancer (Rebbeck 2017). These and other health
51 inequities arise from a complex combination of socioeconomic, demographic,
52 environmental, and genetic causes. Socioeconomic factors like poverty and lack of
53 access to quality treatment are known to increase chronic kidney disease risks (Nicholas,
54 et al. 2015). Similarly, environmental factors like exposure to abandoned uranium mines
55 have been reported to increase risks of hypertension, kidney disease, and cancer in some
56 Native American populations (Lewis, et al. 2017). A population’s genetic makeup can also

57 impact disease susceptibility. For example, some women of Ashkenazi descent carry
58 mutations in *BRCA1* and *BRCA2*, which subjects them to higher risks of breast cancer
59 (Struewing, et al. 1997). We note that the narrow sense heritabilities of many complex
60 diseases exceed 30%, i.e., a substantial proportion of the variance in disease risk is due
61 to genetics (Visscher, et al. 2012).

62 The past decade has seen an upsurge in our collective understanding of the
63 genetics of complex diseases. Genome-wide association studies (GWAS) have identified
64 large numbers of disease-associated SNPs (Sollis, et al. 2023), and these SNPs can be
65 used to generate polygenic predictions of disease risk (Lewis and Vassos 2020). One
66 important lesson learned from GWAS is that most high-mortality non-communicable
67 diseases are polygenic (Torkamani, et al. 2018), i.e., hereditary disease risks are due to
68 the cumulative effects of many single nucleotide polymorphisms. Allele frequencies of
69 disease-associated SNPs often vary among human populations, which in turn causes
70 hereditary disease risks to vary across the globe (Adeyemo and Rotimi 2010). Multiple
71 evolutionary phenomena contribute to population-level differences in allele frequencies,
72 including natural selection (Lohmueller, et al. 2011) and stochastic processes like genetic
73 drift and population bottlenecks (Tishkoff and Verrelli 2003; Chheda, et al. 2017).
74 However, it is presently unknown how much natural selection, as opposed to neutral
75 evolution, contributes to global health inequities.

76 Here, we focus on the ten hereditary diseases with the largest global disease
77 burden in terms of mortality rates (Figure 1). Leveraging findings from multiple recent
78 GWAS, we apply tests of natural selection to sets of disease-associated SNPs. We

79 address the following questions: 1) On a species level, have complex diseases
80 experienced purifying selection? 2) To what extent are population-level differences in
81 hereditary disease burdens due to polygenic adaptation and natural selection? 3) Are our
82 findings robust to different ascertainment patterns of GWAS?

83

84 **New Approaches**

85 This paper examines whether sets of disease-associated SNPs are enriched for
86 signatures of natural selection. As such, it focuses on signatures of selection acting on
87 traits, as opposed to individual SNPs. Due to the highly polygenic nature of complex
88 diseases, most individual SNPs have small effect sizes. However, significant evolutionary
89 forces may be at play when multiple low-effect variants collectively contribute to disease
90 susceptibility. Most existing tests of selection focus on individual SNPs or genes, including
91 B-statistics, which identify loci under purifying selection (McVicker, et al. 2009), and
92 integrative haplotype scores (iHS), which identify loci under recent positive selection
93 (Johnson and Voight 2018). Recently, methods such as PolyGraph have been developed
94 to identify selection acting on sets of SNPs (Racimo, et al. 2018). However, PolyGraph
95 only focuses on adaptive evolution and does not leverage haplotype homozygosity
96 information. Here, we adopt a polygenic framework that leverages B-statistics and iHS
97 values to identify diseases that have been subject to purifying selection or recent positive
98 selection.

99 Our approach consolidates SNP-level information to identify whether trait-
100 associated SNPs are enriched for outlier values of test statistics compared to control

101 SNPs. Recognizing that each SNP does not contribute equally to disease risk, we account
102 for their varying effects by weighting each data point by its effect size; outlier SNPs count
103 more in our trait-level selection tests if they have large effect sizes. For each set of
104 disease-associated SNPs, we obtained 1000 sets of matched control SNPs. These
105 control SNPs are matched with respect to allele frequency, linkage disequilibrium (LD)
106 patterns in the ascertained populations, gene density, and distance to the nearest gene.
107 For each SNP set, we identify the proportion of SNPs, weighted by effect size, that
108 exceeds an accepted outlier threshold ($B < 0.317$ for tests of background selection and
109 $|iHS| > 1.96$ for tests of recent positive selection, see Methods). Enrichment tests involve
110 comparing outlier proportions of disease-associated SNP sets to control sets to generate
111 a percentile rank, with higher percentiles indicating greater trait-level signatures of
112 selection (supplementary Fig. S1). Our approach differs from that of other research teams
113 (Abraham, et al. 2022) in that we look for outlier enrichment, as opposed to trait averages,
114 plus we weigh each SNP by effect size. Additional details can be found in the Methods
115 section.

116

117 **Results**

118 **Global differences in the mortality rates of polygenic diseases**

119 Here, we focus on hereditary diseases that have the largest public health burden. Well-
120 powered GWAS data exist for ten of the top twenty global causes of death, as reported
121 by the WHO (World Health Organization 2020). These maladies are mostly comprised of
122 cardiometabolic diseases, certain cancers, and neurological disorders (Table 1).

123 Although these diseases have the highest burden on a global scale, populations around
124 the world differ significantly in their mortality rates, exceeding an order of magnitude in
125 some cases. Focusing on nine countries that have comparable populations in the 1000
126 Genomes Project (1KGP) (1000 Genomes Project Consortium 2015), the heatmap in
127 Figure 1 depicts mortality rates per 100,000 individuals for the ten polygenic diseases
128 that have the largest global health burden. As seen in Figure 1, European countries have
129 noticeably lower mortality rates of ischemic heart disease and stroke compared to other
130 nations. By contrast, mortality rates of diabetes mellitus are considerably higher in South
131 Asian and African countries. While socioeconomic and lifestyle factors play a
132 considerable role in shaping mortality rates, these disparities can also be due to allele
133 frequency differences at disease-associated loci.

134 To investigate natural selection acting on complex polygenic diseases, we
135 compiled germline variants associated with the disease from publicly available GWAS
136 data (Table 1). Using a pruning and thresholding approach, we obtained sets of
137 independent SNPs associated for each disease. These sets of disease-associated SNPs
138 were then used to test for polygenic signatures of background selection on a species-
139 level, adaptation acting on continental scales, and recent positive selection in individual
140 populations. Due to sample size and statistical power considerations, the main text of this
141 paper primarily focuses on germline variants ascertained in European-ancestry GWAS.
142 However, we later explore the impact of ascertainment bias and validate our results using
143 germline variants ascertained in East Asian and multi-ancestry GWAS.

144

145 **Evidence of background selection on a species level**

146 Background selection (BGS) refers to reduced genetic diversity at a non-deleterious locus
147 caused by negative selection against linked deleterious alleles. This term emphasizes
148 that a neutral mutation's genomic environment or genetic background significantly
149 influences whether it will be preserved or eliminated from a population. BGS has
150 previously been shown to affect linkage disequilibrium patterns and the distribution of
151 heritable variation across the genome (Gazal, et al. 2017; Zeng, et al. 2018; O'Connor, et
152 al. 2019; Wendt, et al. 2021).

153 Given that BGS can influence the genetic architecture of complex traits, we tested
154 whether SNPs that are associated with common polygenic diseases have undergone
155 background or purifying selection. We used pre-computed B-statistics (McVicker, et al.
156 2009) to measure the impact of BGS near individual genomic loci. These statistics
157 quantify the expected amount of genetic diversity flanking a given site in the genome. We
158 extended the B-statistic framework to trait-level analyses by quantifying the extent that
159 sets of disease-associated SNPs are enriched for outliers (see New Approaches and
160 Methods).

161 SNPs that are associated with complex diseases are enriched for signatures of
162 BGS. Figure 2 shows the percentile rank for each set of disease-associated SNPs
163 compared to matched control sets. Percentile ranks range from 88.0 (colon cancer) to
164 above 99.9 (chronic kidney disease and hypertensive heart disease), indicating that
165 disease-associated SNPs are more likely to have outlier values of B-statistics. Overall, 8
166 out of 10 diseases had percentile ranks above 95, a fraction that was statistically
167 significant ($p\text{-value} = 1.605 \times 10^{-9}$, one-tailed binomial test). We note that these trait-level

168 signatures of BGS are not simply due to disease-associated SNPs being found in
169 functional regions of the genome, as control sets are matched for distance to the nearest
170 gene. Our background selection analyses focused on variation existing on a species-
171 level. We next turn to signatures of selection acting on continental scales.

172

173 **Minimal signatures of polygenic adaptation on a continental scale**

174 Polygenic adaptation occurs through slight shifts in allele frequency at multiple loci
175 (Barghi, et al. 2020). Although individual allele frequency changes may be small, their
176 collective impact on the disease can be substantial. Disease-associated SNPs often vary
177 in their allele frequencies across global populations (Kim, et al. 2018). Thus, we used
178 PolyGraph (Racimo, et al. 2018) to quantify if such differences are driven by polygenic
179 adaptation for the ten complex diseases. PolyGraph detects adaptation of polygenic traits
180 due to allele frequency shifts at multiple loci using an admixture graph framework that
181 considers the historical divergence of populations. It makes use of the ancestral and
182 derived allele frequencies for each disease-associated loci at every population in the tree
183 along with their effect sizes and compares them to a control distribution.

184 Tests of polygenic adaptation for the ten hereditary diseases with the largest public
185 health burden are shown in Fig. 3. Although PolyGraph identifies weak signals of
186 polygenic adaptation on some branches, FDR-adjusted q-values do not pass the
187 threshold of statistical significance for most diseases. Branch-specific statistics from
188 PolyGraph for each disease are listed in supplementary File S. Visually, this is illustrated
189 by the preponderance of gray branches in Fig. 3. Although there are instances of
190 branches with non-zero selection parameters (blue and red branches coloration in Fig.

191 3), these patterns were not replicated in PolyGraph analyses that used SNPs that were
192 ascertained in other non-European GWAS (supplementary Figs. S2 and S3). Collectively,
193 our PolyGraph analyses indicate that genetic drift is the primary cause of continental
194 differences in allele frequencies for the diseases analyzed here. Subsequent tests of
195 selection zoom in on individual populations.

196

197 **Sparse signatures of recent positive selection on a local scale**

198 To identify diseases under recent positive selection, we employ the integrated Haplotype
199 Score (iHS), which can identify partial selective sweeps from stretches of extended
200 haplotype homozygosity. iHS statistics are normalized based on a genome-wide empirical
201 distribution, and extreme negative or positive iHS scores are considered potential
202 indicators of recent positive selection ($|iHS| > 1.96$). Given iHS's emphasis on more recent
203 selection, we narrowed our scope from major continental populations to 26 diverse
204 populations from the 1KGP.

205 We performed an enrichment analysis to test if SNPs sets associated with each of
206 the ten diseases are enriched for outlier iHS values when compared to controls. These
207 analyses were repeated for all 26 populations in the 1KGP (Fig. 4). Higher percentiles in
208 these polygenic tests are indicative of enrichment for outlier iHS values, i.e., recent
209 positive selection. Notably, most diseases show low percentile values in all 26
210 populations, implying that the complex diseases analyzed in this study are not major
211 targets of recent positive selection. Overall, only 6 out of 260 tests had percentile ranks
212 above 95 when compared to controls (p -value = 0.9906, one-tailed binomial test).

213 Interestingly, ischemic heart disease shows some enrichment for outlier iHS values
214 in South Asian populations, while hypertensive heart disease exhibits the most
215 pronounced enrichment in genomes from Lima, Peru (PUR). The Peruvian population
216 also demonstrates enrichment for other diseases when tested with SNP sets ascertained
217 in non-European populations. Recent studies have shown evidence of associations
218 between cardiovascular disease and adaptation to high altitude in Peruvian populations
219 (Caro-Consuegra, et al. 2022; Hernandez-Vasquez, et al. 2022). These findings, along
220 with our results, suggest that adaptive alleles may have pleiotropic effects with respect to
221 disease risks. However, it is crucial to note that none of the observed percentile scores
222 are high enough to withstand Bonferroni corrections.

223

224 **Robustness of our findings to ascertainment bias**

225 A major challenge when using GWAS data is ascertainment bias (Kim, et al. 2018). The
226 ability to infer disease associations relies on allele frequencies being within an
227 intermediate range in the discovery population, coupled with substantial effect sizes. This
228 means that sets of disease-associated SNPs can differ across studies, particularly when
229 the ancestries of study participants differ. This inherent variability in SNP sets and effect
230 sizes can potentially yield varying outcomes in tests of polygenic selection. In this paper,
231 we comprehensively address the issue of ascertainment bias by evaluating whether the
232 conclusions of our polygenic tests of natural selection are similar for GWAS SNPs that
233 were ascertained in different populations. When possible, we analyzed three different
234 ascertainment schemes for each disease, i.e., SNP sets that were ascertained in
235 European, East Asian, and multi-ancestry GWAS (Table 1).

236 Our tests of polygenic selection reveal consistent patterns regardless of the
237 ancestry of the original source GWAS (Table 1). Although isolated exceptions exist, we
238 found that disease-associated SNPs were strongly enriched for signatures of BGS
239 regardless of whether the original GWAS was European, East Asian, or multi-ancestry
240 (compare Fig. 2 and supplementary Figs. S4 and S5). Similarly, tests of positive selection
241 acting on continental and local scales revealed that most differences in complex disease
242 risks are not driven by natural selection. Although there were slightly stronger signatures
243 of positive selection for SNPs that were ascertained in East Asian GWAS, PolyGraph
244 results were largely robust to GWAS ancestry (compare Fig. 3 and supplementary Figs.
245 S2 and S3). The haplotype homozygosity of disease-associated variants did not
246 appreciably differ from that of control sets, and this pattern was consistent across
247 ancestries (compare Fig. 4 and supplementary Figs. S6 and S7). Although the detectable
248 genetic architectures of complex diseases may differ between populations, the genomic
249 signatures of selection acting on these traits are largely robust to ascertainment bias.

250

251 **Discussion**

252 Focusing on the ten diseases with the largest global health burden, we tested whether
253 sets of disease-associated SNPs are enriched for signatures of natural selection. B-
254 statistics revealed that most complex diseases have been subject to purifying selection
255 on a species-level. Results from Polygraph and iHS statistics were largely negative. This
256 implies that recent positive selection has not been a major driver of population-level
257 differences in the risks of polygenic diseases.

258 Complex disease risks appear to have evolved neutrally over recent human
259 history. Although frequencies of disease-associated alleles differ between populations,
260 these differences are largely due to genetic drift. Population genetics theory reveals that
261 effects of genetic drift are inversely proportional to effective population size. Because of
262 this, population bottlenecks and serial founder effects are likely to have had an outsized
263 role in the divergence of hereditary disease risks across human populations (Keinan, et
264 al. 2007). Our results are consistent with prior studies that that have found minimal
265 evidence of selection in traits like type 2 diabetes in the Polynesians (Sun, et al. 2021).
266 We note that our study focused on polygenic signatures of selection. Exceptions to this
267 general pattern exist for a small subset of disease-associated loci, and future studies
268 examining whether these exceptions are due to pleiotropy or genetic hitchhiking are likely
269 to be fruitful.

270 Socioeconomic factors likely contribute more to differences in disease burden than
271 genetic differences at trait-associated SNPs. Although many complex diseases have
272 substantial heritabilities (Visscher, et al. 2012), these traits are highly polygenic and allele
273 frequency differences at numerous loci of small effect loci can balance out. Other factors,
274 like education, income, and access to health care, play a large role in determining
275 mortality rates. Indeed, the Human Development Index (HDI) is correlated with many
276 public health statistics. For example, mortality rates of colorectal cancer are high in
277 countries that have a high HDI, while mortality rates of ischemic heart disease are high in
278 countries that have a low HDI (UNDP 2022). An intriguing avenue of future research

279 involves quantifying how much genotype-environment interactions contribute to health
280 disparities (Rosenberg, et al. 2019).

281 One potential limitation of our study is that it relies on disease associations inferred
282 from GWAS. By necessity, GWAS hits are subject to ascertainment bias. However, our
283 findings are robust to differences in the ancestries of discovery cohorts. Furthermore, the
284 “known unknowns” (Kim, et al. 2018), i.e., alleles of small effect that have yet to be
285 implicated in a GWAS, are unlikely to change the conclusions of this paper. Each of these
286 as-yet-undiscovered disease associations makes only a small contribution to heritability
287 and their collective summary statistics are expected to resemble genome-wide baselines
288 (Carvalho, et al. 2022). Regardless, genetic differences in disease burdens across human
289 populations appear to be governed more by neutral evolution than by natural selection.

290

291 **Methods**

292 **Datasets**

293 We conducted a comprehensive analysis of genome-wide association studies (GWAS)
294 encompassing ten diseases across three distinct ascertaining populations: European,
295 East Asian, and multi-ancestry (Table 1). Notably, due to an insufficient number of
296 significant associations identified for Alzheimer’s Disease in East Asian and multi-
297 ancestry ascertained GWAS, we excluded this trait from ascertainment bias testing.
298 Significant SNPs with a p-value $< 5 \times 10^{-5}$ were extracted from each GWAS. Subsequently,
299 LD pruning was performed to isolate independent associations with an $r^2 < 0.2$ within the
300 respective ascertained population, utilizing Plink 1.9 (Chang, et al. 2015) and 1KGP

301 phase 3 data (1000 Genomes Project Consortium 2015) as a reference. To ensure
302 uniformity, the LiftOver tool (Hinrichs, et al. 2006) was employed to convert all coordinates
303 of all GWAS SNPs to the hg19 build.

304 In all our analyses, control SNPs were obtained using SNPSnap (Pers, et al.
305 2015). Matching criteria included allele frequency, LD patterns, distance to gene, and
306 gene density in the ascertained population. SNPs within the HLA region were removed.
307 For European and East Asian ascertained GWAS, controls were matched within their
308 respective populations from the 1KGP. In the case of multi-ancestry studies, controls
309 were matched across pooled data from European, East Asian, and African populations to
310 yield sets of SNPs.

311

312 **Trait-level distributions of summary statistics**

313 For the enrichment analyses, our focus is on assessing whether sets of disease-
314 associated SNPs, considered collectively, have undergone selection. To integrate the
315 SNP-level information from test statistics into a comprehensive trait-level distribution, we
316 employ kernel density estimation (KDE). This method allows us to derive a probability
317 distribution of the test statistic for each trait. Unlike traditional estimation techniques, KDE
318 is a nonparametric approach that does not assume that the data follows a known
319 distribution. Instead, nonparametric models determine the structure from the underlying
320 data itself. In our implementation, we opt for a Gaussian kernel and conduct a five-fold
321 cross-validation using GridSearchCV (Pedregosa 2011) to determine the optimal kernel
322 bandwidth for the KDE. Since each associated SNP also has a strength of association to

323 the disease (beta or effect size), we also weigh the SNPs according to their absolute
324 effect sizes while implementing KDE. The outcome of KDE is a probability density function
325 (PDF) with the area under the curve standardized to one.

326

327 **Outlier Enrichment: Background Selection**

328 We use B-statistic as a measure of background selection. B indicates the expected
329 fraction of neutral diversity present at a site, with values close to 0 representing near
330 complete removal of diversity due to selection and values near 1 indicating little effect.
331 Using BEDTools (Quinlan and Hall 2010), we extracted B values for SNPs from GWAS
332 and their matched controls.

333 To check for background selection enrichment, we focus on lower B-values and
334 calculate the probability of the trait having a B value less than 0.317 (area under the PDF
335 from 0 to 0.317, $AUC_{0.317}$). Previous research suggests a B value of around 0.317 is a
336 threshold for the lowest 5% of B values across the human genome (Torres, et al.
337 2018). We create PDFs for 1000 matched control sets using similar KDE steps described
338 above. We estimate the probability of having a B-statistic of less than 0.317 in the control
339 sets, where the SNPs are not linked to the disease but have similar allele frequencies
340 and distances to genes. Comparing the $AUC_{0.317}$ of the trait to the 1000 control $AUC_{0.317}$
341 gives us a percentile rank for the trait. A high percentile rank indicates that trait-associated
342 SNPs are enriched for outlier B-statistics (supplementary Fig. S1A).

343 Previous research has demonstrated that the B-statistic, while prone to potential
344 misestimation and influenced by the assumptions of the underlying model, reliably

345 preserves the correct rank order of SNPs (Comeron 2014; Torres, et al. 2018). Thus, we
346 expect McVicker et al.'s inference of B to provide good separation between the regions
347 experiencing the weakest and strongest background selection effects at linked sites within
348 the human genome. Nevertheless, to ensure the robustness of our findings, we
349 conducted additional enrichment analyses using more stringent B-statistic thresholds (0.2
350 and 0.1) and obtained consistent results (supplementary Fig. S8).

351

352 **Outlier Enrichment: Recent Positive Selection**

353 We use an integrated Haplotype Score (iHS) to measure recent positive selection in 26
354 global populations from the 1KGP (Johnson and Voight 2018). iHS values are assigned
355 to each SNP in the genome and are normalized, with negative values indicating selection
356 of the derived allele and positive values indicating selection of the ancestral allele. Since
357 the iHS value is normalized genome-wide, any SNP with a value two standard deviations
358 away from the mean i.e., $|iHS| > 1.96$, is operationally considered to be under selection
359 (Voight, et al. 2006).

360 Following the method detailed earlier, we construct trait-associated and 1000
361 control set distributions using kernel density estimation (KDE). Subsequently, we
362 calculate the probability of iHS values exceeding 1.96 or falling below -1.96 in both the
363 trait and control distributions. We then derive a percentile rank for the trait AUC in
364 comparison to the 1000 control sets. Higher percentile ranks signify that the trait exhibits
365 more extreme iHS values compared to the controls (see supplementary Fig. S1B).

366

367 **Polygenic Adaptation**

368 To investigate signals of polygenic adaptation, we use PolyGraph (Racimo, et al. 2018),
369 a Markov Chain Monte Carlo (MCMC) algorithm that utilizes admixture graph information
370 to deduce traces of polygenic adaptation in populations. To detect selection on a trait
371 PolyGraph requires a set of summary statistics from GWAS, neutral or control SNPs that
372 are not associated with the trait, and an admixture graph of the representative
373 populations. PolyGraph requires knowledge of the ancestral alleles of all GWAS hits to
374 polarize effect sizes. Thus, only GWAS hits where ancestral allele information was
375 available from the 1KGP dataset were used in our study.

376 The same set of control SNPs used for the enrichment analyses was used to build
377 an admixture graph using MixMapper (Lipson, et al. 2014). We made scaffold trees with
378 eight continental populations and added the population from Peru (PEL) as an admixed
379 population (note that one branch leading to PEL represents Native American ancestry).
380 We ran PolyGraph with its default parameters using 1,000,000 MCMC steps. PolyGraph
381 reports a selection parameter alpha for each disease, a product of the selection coefficient
382 for the advantageous allele and the duration of the selective process, and a p-value for
383 selection on the entire admixture graph. To correct for multiple testing, we calculated
384 FDR-adjusted q-values from the overall p-values of selection from PolyGraph (Table 1).

385

386 **Supplementary Material**

387 Supplementary material includes supplementary File S1 (.xlsx) and a merged .pdf
388 containing supplementary Figs. S1-S8.

389

390 **Acknowledgments**

391 We thank Rohini Janivara, Aaron Pfennig, Mimi Holness, and members of the Center for
392 Integrative Genomics at Georgia Institute of Technology for their insight and helpful
393 comments. This work was supported by an NIH MIRA grant (R35GM133727). The
394 funders did not have any role in this article's design, analysis, or writing.

395

396 **Author contributions**

397 U.H and J.L. conceived this study and developed methodology. U.H. curated GWAS
398 datasets, conducted polygenic tests of selection, and performed data visualization. J.L.
399 supervised this research and provided funding. U.H. and J.L. wrote and edited this
400 manuscript.

401 *Conflict of interest statement:* None declared.

402

403 **Data Availability**

404 The GWAS summary statistics used in this paper are publicly available. Details about
405 specific studies can be found in Table 1.

406

407 **References**

408 1000 Genomes Project Consortium. 2015. A global reference for human genetic
409 variation. *Nature* 526:68.

410 Abraham A, LaBella AL, Capra JA, Rokas A. 2022. Mosaic patterns of selection in
411 genomic regions associated with diverse human traits. *PLoS Genet* 18:e1010494.

- 412 Adeyemo A, Rotimi C. 2010. Genetic variants associated with complex human diseases
413 show wide variation across multiple populations. *Public Health Genomics* 13:72-79.
- 414 Allen L, Cobiac L, Townsend N. 2017. Quantifying the global distribution of premature
415 mortality from non-communicable diseases. *J Public Health (Oxf)* 39:698-703.
- 416 Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M,
417 Hindy G, Zhou W, et al. 2022. Discovery and systematic characterization of risk variants
418 and genes for coronary artery disease in over a million participants. *Nat Genet* 54:1803-
419 1815.
- 420 Armstrong GL, Conn LA, Pinner RW. 1999. Trends in infectious disease mortality in the
421 United States during the 20th century. *JAMA* 281:61-66.
- 422 Barghi N, Hermisson J, Schlotterer C. 2020. Polygenic adaptation: a unifying framework
423 to understand positive selection. *Nat Rev Genet* 21:769-781.
- 424 Bellenguez C, Kucukali F, Jansen IE, Kleiheidam L, Moreno-Grau S, Amin N, Naj AC,
425 Campos-Martin R, Grenier-Boley B, Andrade V, et al. 2022. New insights into the
426 genetic etiology of Alzheimer's disease and related dementias. *Nat Genet* 54:412-436.
- 427 Bigna JJ, Noubiap JJ. 2019. The rising burden of non-communicable diseases in sub-
428 Saharan Africa. *Lancet Glob Health* 7:e1295-e1296.
- 429 Byun J, Han Y, Li Y, Xia J, Long E, Choi J, Xiao X, Zhu M, Zhou W, Sun R, et al. 2022.
430 Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls
431 identifies new susceptibility loci contributing to lung cancer. *Nat Genet* 54:1167-1177.
- 432 Cai L, Wheeler E, Kerrison ND, Luan J, Deloukas P, Franks PW, Amiano P, Ardanaz E,
433 Bonet C, Fagherazzi G, et al. 2020. Genome-wide association analysis of type 2
434 diabetes in the EPIC-InterAct study. *Sci Data* 7:393.
- 435 Caro-Consuegra R, Nieves-Colon MA, Rawls E, Rubin-de-Celis V, Lizarraga B,
436 Vidaurre T, Sandoval K, Fejerman L, Stone AC, Moreno-Estrada A, et al. 2022.

- 437 Uncovering Signals of Positive Selection in Peruvian Populations from Three Ecological
438 Regions. *Mol Biol Evol* 39.
- 439 Carvalho NRG, Harris AM, Lachance J. 2022. Different genetic architectures of complex
440 traits and their relevance to polygenic score performance.
441 [bioRxiv:2022.2010.2029.514295](https://doi.org/10.1101/2022.2010.2029.514295).
- 442 Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. 2015. Second-
443 generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4:7.
- 444 Chheda H, Palta P, Pirinen M, McCarthy S, Walter K, Koskinen S, Salomaa V, Daly M,
445 Durbin R, Palotie A, et al. 2017. Whole-genome view of the consequences of a
446 population bottleneck using 2926 genome sequences from Finland and United
447 Kingdom. *Eur J Hum Genet* 25:477-484.
- 448 Comeron JM. 2014. Background selection as baseline for nucleotide variation across
449 the *Drosophila* genome. *PLoS Genet* 10:e1004434.
- 450 Corbett S, Courtiol A, Lummaa V, Moorad J, Stearns S. 2018. The transition to
451 modernity and chronic disease: mismatch and natural selection. *Nat Rev Genet* 19:419-
452 430.
- 453 Crespi BJ. 2010. The origins and evolution of genetic disease risk in modern humans.
454 *Ann N Y Acad Sci* 1206:80-109.
- 455 Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S, Diez-
456 Obrero V, Hsu L, Fernandez-Tajes J, Palles C, et al. 2023. Deciphering colorectal
457 cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of
458 European and east Asian ancestries. *Nat Genet* 55:89-99.
- 459 Gazal S, Finucane HK, Furlotte NA, Loh PR, Palamara PF, Liu X, Schoech A, Bulik-
460 Sullivan B, Neale BM, Gusev A, et al. 2017. Linkage disequilibrium-dependent

- 461 architecture of human complex traits shows action of negative selection. *Nat Genet*
462 49:1421-1427.
- 463 Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, Torstenson ES, Kovesdy
464 CP, Sun YV, Wilson OD, et al. 2019. Trans-ethnic association study of blood pressure
465 determinants in over 750,000 individuals. *Nat Genet* 51:51-62.
- 466 Hernandez-Vasquez A, Vargas-Fernandez R, Chacon-Diaz M. 2022. Association
467 between Altitude and the Framingham Risk Score: A Cross-Sectional Study in the
468 Peruvian Adult Population. *Int J Environ Res Public Health* 19.
- 469 Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, Diekhans M,
470 Furey TS, Harte RA, Hsu F, et al. 2006. The UCSC Genome Browser Database: update
471 2006. *Nucleic Acids Res* 34:D590-598.
- 472 Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S,
473 Matoba N, Low SK, Okada Y, et al. 2020. Large-scale genome-wide association study
474 in a Japanese population identifies novel susceptibility loci across different diseases.
475 *Nat Genet* 52:669-679.
- 476 Johnson KE, Voight BF. 2018. Patterns of shared signatures of recent positive selection
477 across human populations. *Nat Ecol Evol* 2:713-720.
- 478 Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, Iwata N,
479 Ikegawa S, Hirata M, Matsuda K, et al. 2018. Genetic analysis of quantitative traits in
480 the Japanese population links cell types to complex human diseases. *Nat Genet*
481 50:390-400.
- 482 Keinan A, Mullikin JC, Patterson N, Reich D. 2007. Measurement of the human allele
483 frequency spectrum demonstrates greater genetic drift in East Asians than in
484 Europeans. *Nat Genet* 39:1251-1255.

- 485 Kim AS, Johnston SC. 2011. Global variation in the relative burden of stroke and
486 ischemic heart disease. *Circulation* 124:314-323.
- 487 Kim MS, Patel KP, Teng AK, Berens AJ, Lachance J. 2018. Genetic disease risks can
488 be misestimated across global populations. *Genome Biol* 19:179.
- 489 Law PJ, Timofeeva M, Fernandez-Rozadilla C, Broderick P, Studd J, Fernandez-Tajes
490 J, Farrington S, Svinti V, Palles C, Orlando G, et al. 2019. Association analyses identify
491 31 new risk loci for colorectal cancer susceptibility. *Nat Commun* 10:2154.
- 492 Lewis CM, Vassos E. 2020. Polygenic risk scores: from research tools to clinical
493 instruments. *Genome Med* 12:44.
- 494 Lewis J, Hoover J, MacKenzie D. 2017. Mining and Environmental Health Disparities in
495 Native American Communities. *Curr Environ Health Rep* 4:130-141.
- 496 Lipson M, Loh PR, Patterson N, Moorjani P, Ko YC, Stoneking M, Berger B, Reich D.
497 2014. Reconstructing Austronesian population history in Island Southeast Asia. *Nat*
498 *Commun* 5:4689.
- 499 Lohmueller KE, Albrechtsen A, Li Y, Kim SY, Korneliussen T, Vinckenbosch N, Tian G,
500 Huerta-Sanchez E, Feder AF, Grarup N, et al. 2011. Natural selection affects multiple
501 aspects of genetic variation at putatively neutral sites across the human genome. *PLoS*
502 *Genet* 7:e1002326.
- 503 Lu Y, Kweon SS, Cai Q, Tanikawa C, Shu XO, Jia WH, Xiang YB, Huyghe JR, Harrison
504 TA, Kim J, et al. 2020. Identification of Novel Loci and New Risk Variant in Known Loci
505 for Colorectal Cancer Risk in East Asians. *Cancer Epidemiol Biomarkers Prev* 29:477-
506 486.
- 507 Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, Yu GZ, Rueger S,
508 Speidel L, Kim YJ, et al. 2022. Multi-ancestry genetic study of type 2 diabetes highlights
509 the power of diverse populations for discovery and translation. *Nat Genet* 54:560-572.

- 510 Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs
511 L, Giese AK, van der Laan SW, Gretarsdottir S, et al. 2018. Multiancestry genome-wide
512 association study of 520,000 subjects identifies 32 loci associated with stroke and
513 stroke subtypes. *Nat Genet* 50:524-537.
- 514 Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH,
515 Wang Q, Bolla MK, et al. 2019. Polygenic Risk Scores for Prediction of Breast Cancer
516 and Breast Cancer Subtypes. *Am J Hum Genet* 104:21-34.
- 517 McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE,
518 Johansson M, Xiao X, Li Y, et al. 2017. Large-scale association analysis identifies new
519 lung cancer susceptibility loci and heterogeneity in genetic susceptibility across
520 histological subtypes. *Nat Genet* 49:1126-1132.
- 521 McVicker G, Gordon D, Davis C, Green P. 2009. Widespread genomic signatures of
522 natural selection in hominid evolution. *PLoS Genet* 5:e1000471.
- 523 Mishra A, Malik R, Hachiya T, Jurgenson T, Namba S, Posner DC, Kamanu FK, Koido
524 M, Le Grand Q, Shi M, et al. 2022. Stroke genetics informs drug discovery and risk
525 prediction across ancestries. *Nature* 611:115-123.
- 526 Mummert A, Esche E, Robinson J, Armelagos GJ. 2011. Stature and robusticity during
527 the agricultural transition: evidence from the bioarchaeological record. *Econ Hum Biol*
528 9:284-301.
- 529 Nicholas SB, Kalantar-Zadeh K, Norris KC. 2015. Socioeconomic disparities in chronic
530 kidney disease. *Adv Chronic Kidney Dis* 22:6-15.
- 531 O'Connor LJ, Schoech AP, Hormozdiari F, Gazal S, Patterson N, Price AL. 2019.
532 Extreme Polygenicity of Complex Traits Is Explained by Negative Selection. *Am J Hum*
533 *Genet* 105:456-476.

534 Pedregosa F, Varoquaux, G. , Gramfort, A. , Michel, V. , Thirion, B. , Grisel, O. ,
535 Blondel, M. , Prettenhofer, P. , Weiss, R. , Dubourg, V. , Vanderplas, J. , Passos, A. ,
536 Cournapeau, D. a, Brucher, M. , Perrot, M. ,Duchesnay, E. 2011. Scikit-learn: Machine
537 Learning in Python. *Journal of Machine Learning Research* 12:2825--2830.

538 Pers TH, Timshel P, Hirschhorn JN. 2015. SNPsnap: a Web-based tool for identification
539 and annotation of matched SNPs. *Bioinformatics* 31:418-420.

540 Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic
541 features. *Bioinformatics* 26:841-842.

542 Quintana-Murci L. 2016. Understanding rare and common diseases in the context of
543 human evolution. *Genome Biol* 17:225.

544 Racimo F, Berg JJ, Pickrell JK. 2018. Detecting Polygenic Adaptation in Admixture
545 Graphs. *Genetics* 208:1565-1584.

546 Rebbeck TR. 2017. Prostate Cancer Genetics: Variation by Race, Ethnicity, and
547 Geography. *Semin Radiat Oncol* 27:3-10.

548 Rosenberg NA, Edge MD, Pritchard JK, Feldman MW. 2019. Interpreting polygenic
549 scores, polygenic adaptation, and human phenotypic differences. *Evol Med Public*
550 *Health* 2019:26-34.

551 Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, Batini
552 C, Fawcett KA, Song K, Sakornsakolpat P, et al. 2019. New genetic signals for lung
553 function highlight pathways and chronic obstructive pulmonary disease associations
554 across multiple ancestries. *Nat Genet* 51:481-493.

555 Shrine N, Izquierdo AG, Chen J, Packer R, Hall RJ, Guyatt AL, Batini C, Thompson RJ,
556 Pavuluri C, Malik V, et al. 2023. Multi-ancestry genome-wide association analyses
557 improve resolution of genes and pathways influencing lung function and chronic
558 obstructive pulmonary disease risk. *Nat Genet* 55:410-422.

559 Shu X, Long J, Cai Q, Kweon SS, Choi JY, Kubo M, Park SK, Bolla MK, Dennis J,
560 Wang Q, et al. 2020. Identification of novel breast cancer susceptibility loci in meta-
561 analyses conducted among Asian and European descendants. *Nat Commun* 11:1217.

562 Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Gunes O, Hall P,
563 Hayhurst J, et al. 2023. The NHGRI-EBI GWAS Catalog: knowledgebase and
564 deposition resource. *Nucleic Acids Res* 51:D977-D985.

565 Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, Suzuki K, Tam CHT,
566 Tabara Y, Kwak SH, et al. 2020. Identification of type 2 diabetes loci in 433,540 East
567 Asian individuals. *Nature* 582:240-245.

568 Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman
569 MM, Brody LC, Tucker MA. 1997. The risk of cancer associated with specific mutations
570 of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 336:1401-1408.

571 Sun H, Lin M, Russell EM, Minster RL, Chan TF, Dinh BL, Naseri T, Reupena MS, Lum-
572 Jones A, Samoan Obesity L, et al. 2021. The impact of global and local Polynesian
573 genetic ancestry on complex traits in Native Hawaiians. *PLoS Genet* 17:e1009273.

574 Surendran P, Feofanova EV, Lahrouchi N, Ntalla I, Karthikeyan S, Cook J, Chen L,
575 Mifsud B, Yao C, Kraja AT, et al. 2020. Discovery of rare variants associated with blood
576 pressure regulation through meta-analysis of 1.3 million individuals. *Nat Genet* 52:1314-
577 1332.

578 Tcheandjieu C, Zhu X, Hilliard AT, Clarke SL, Napolioni V, Ma S, Lee KM, Fang H,
579 Chen F, Lu Y, et al. 2022. Large-scale genome-wide association study of coronary
580 artery disease in genetically diverse populations. *Nat Med* 28:1679-1692.

581 Tishkoff SA, Verrelli BC. 2003. Patterns of human genetic diversity: implications for
582 human evolutionary history and disease. *Annu Rev Genomics Hum Genet* 4:293-340.

- 583 Torkamani A, Wineinger NE, Topol EJ. 2018. The personal and clinical utility of
584 polygenic risk scores. *Nat Rev Genet* 19:581-590.
- 585 Torres R, Szpiech ZA, Hernandez RD. 2018. Human demographic history has amplified
586 the effects of background selection across the genome. *PLoS Genet* 14:e1007387.
- 587 UNDP. 2022. Human Development Report 2021-22. UNDP (United Nations
588 Development Programme).
- 589 Visscher PM, Brown MA, McCarthy MI, Yang J. 2012. Five years of GWAS discovery.
590 *Am J Hum Genet* 90:7-24.
- 591 Voight BF, Kudaravalli S, Wen X, Pritchard JK. 2006. A map of recent positive selection
592 in the human genome. *PLoS Biol* 4:e72.
- 593 Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL, Lurie N, Rebbeck T,
594 Goodwin J, Flack J, et al. 2008. Approaching health disparities from a population
595 perspective: the National Institutes of Health Centers for Population Health and Health
596 Disparities. *Am J Public Health* 98:1608-1615.
- 597 Wendt FR, Pathak GA, Overstreet C, Tylee DS, Gelernter J, Atkinson EG, Polimanti R.
598 2021. Characterizing the effect of background selection on the polygenicity of brain-
599 related traits. *Genomics* 113:111-119.
- 600 World Health Organization. 2020. Global Health Estimates 2020: deaths by cause A,
601 sex, by country and by region, 2000–2019. WHO; 2020. In.
- 602 Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, Tin A, Wang L, Chu AY,
603 Hoppmann A, et al. 2019. A catalog of genetic loci associated with kidney function from
604 analyses of a million individuals. *Nat Genet* 51:957-972.
- 605 Zeng J, de Vlaming R, Wu Y, Robinson MR, Lloyd-Jones LR, Yengo L, Yap CX, Xue A,
606 Sidorenko J, McRae AF, et al. 2018. Signatures of negative selection in the genetic
607 architecture of human complex traits. *Nat Genet* 50:746-753.

609 **Tables**

610

| Trait | Ascertained Population | B-statistic %ile | PolyGraph q-value | Max iHS %ile (population) |
|-----------------------------|---------------------------------------------------|------------------|------------------------|---------------------------|
| Ischemic Heart Disease | European (Aragam, et al. 2022) | 98.8 | 0.1689 | 98 (ITU) |
| | East Asian (Ishigaki, et al. 2020) | >99.9 | 5.21x10 ⁻¹¹ | >99.9 (TSI) |
| | Multi-ancestry (Tcheandjieu, et al. 2022) | 90.3 | 0.6884 | 86 (PEL) |
| Stroke | European (Malik, et al. 2018) | 98.8 | 0.2951 | 88 (YRI) |
| | East Asian (Ishigaki, et al. 2020) | 95.6 | 0.0941 | 84 (GWD) |
| | Multi-ancestry (Mishra, et al. 2022) | 97.1 | 0.6884 | 74 (IBS) |
| COPD | European (Shrine, et al. 2019) | 98.8 | 0.9245 | 93 (PUR) |
| | East Asian (Ishigaki, et al. 2020) | >99.9 | 0.7000 | 95 (JPT) |
| | Multi-ancestry (Shrine, et al. 2023) | 99.8 | 0.6884 | 89 (GIH, PUR) |
| Lung Cancer | European (McKay, et al. 2017) | 91.8 | 0.9245 | 92 (GBR) |
| | East Asian (Ishigaki, et al. 2020) | 74.9 | 0.1144 | 92 (GBR) |
| | Multi-ancestry (Byun, et al. 2022) | 39.8 | 4.37x10 ⁻⁰⁹ | >99.99 (PEL) |
| Alzheimer's Disease | European (Bellenguez, et al. 2022) | 96.1 | 0.8876 | 94.5 (TSI) |
| Type 2 Diabetes | European (Cai, et al. 2020) | 97.7 | 0.4697 | 85 (JPT) |
| | East Asian (Spracklen, et al. 2020) | 94.1 | 0.1777 | 98 (CLM) |
| | Multi-ancestry (Mahajan, et al. 2022) | 99.9 | 0.6884 | 99 (PEL) |
| Chronic Kidney Disease | European (Wuttke, et al. 2019) | >99.9 | 0.0113 | 98 (CDX, PEL) |
| | East Asian (Kanai, et al. 2018) | >99.9 | 0.0010 | 57 (CHB) |
| | Multi-ancestry (Wuttke, et al. 2019) | >99.9 | 0.3186 | 70 (FIN, GWD) |
| Hypertensive Heart Disorder | European (Surendran, et al. 2020) | >99.9 | 0.0160 | 99 (PEL) |
| | East Asian (Kanai, et al. 2018) | >99.9 | 0.0100 | 96 (ESN) |
| | Multi-ancestry (Giri, et al. 2019) | 99.9 | 0.6884 | 90 (CHS) |
| Colon Cancer | European (Law, et al. 2019) | 88.0 | 0.9245 | 78 (GIH) |
| | East Asian (Lu, et al. 2020) | 99.9 | 0.0061 | 72 (MSL) |
| | Multi-ancestry (Fernandez-Rozadilla, et al. 2023) | 99.7 | 0.7225 | 62 (KHV) |
| Breast Cancer | European (Mavaddat, et al. 2019) | 99.2 | 0.9245 | 89 (CHS) |
| | East Asian (Ishigaki, et al. 2020) | 78.6 | 0.0265 | 81 (CDX) |
| | Multi-ancestry (Shu, et al. 2020) | 98.9 | 0.9716 | 94 (CHS) |


611

612 **Table 1.** Top ten hereditary diseases with the highest global mortality from the 2020 World
 613 Health Organization Report. The second column list ancestries of each source GWAS
 614 used in our study. The third column summarizes the enrichment for BGS on these

615 diseases, comparing results across three ascertainment schemes to 1000 control sets.
616 The fourth column provides insights into polygenic adaptation signals, presenting FDR-
617 adjusted q-values. Finally, the last column list the 1KGP population(s) exhibiting the
618 highest enrichment for extreme iHS values in comparison to 1000 control sets of SNPs.

619 Figures


620



621

622 **Fig. 1.** Heatmap demonstrating the age-standardized mortality rates per 100,000
623 individuals for each disease in nine different countries (World Health Organization 2020).

624 We observe heterogeneity in the mortality rates of each of these diseases. While some
625 differences can be attributed to socioeconomic and lifestyle factors, this paper delves into
626 the genetic contributors to each disease and tests if natural selection and a population's
627 evolutionary history significantly contribute to such inequities.



628

629 **Fig. 2.** Disease associated SNPs are enriched for signatures background selection.

630 Plotted here are results from SNP sets that were ascertained in European ancestry

631 GWAS. The percentile rank for each disease shows disease-associated SNPs are

632 enriched for higher BGS compared to 1000 control sets before correcting for multiple


633 testing, with a dotted line marks the 95th percentile of a control sets. SNP sets that were

634 ascertained in East Asian and multi-ancestry GWAS yielded broadly similar patterns of

635 BGS (supplementary Figs. S4 and S5). As per (Torres, et al. 2018), a B-statistic outlier

636 threshold of 0.317 was used.


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



637

638 **Fig. 3.** Minimal evidence of polygenic adaptation acting on common diseases. Plotted
639 here are results from SNPs sets that were ascertained in European ancestry GWAS.
640 MixMapper was used to generate the admixture graph and PolyGraph was used to test
641 for polygenic signatures of adaptation. FDR-adjusted q-values are above 0.05 for eight
642 out of ten diseases. The selection parameter alpha reports a product of the selection
643 coefficient for the advantageous alleles and the duration of the selective process. SNP
644 sets that were ascertained in East Asian and multi-ancestry GWAS yielded broadly similar
645 patterns of polygenic adaptation (supplementary Figs. S2 and S3).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



646

647 **Fig. 4.** Sparse signals of recent positive selection (partial sweeps) acting on complex
 648 diseases in 26 global populations from the 1KGP. Plotted here are results from SNPs
 649 sets that were ascertained in European ancestry GWAS. Percentile ranks quantify how
 650 much disease-associated loci are enriched for outlier iHS values compared to 1000 sets
 651 of control SNPs. Outlier threshold: $|iHS| > 1.96$. Population acronyms are from the 1KGP.
 652 SNP sets that were ascertained in East Asian and multi-ancestry GWAS yielded broadly
 653 similar patterns (supplementary Figs. S6 and S7).